Table 1 The relationship between the high and low expression of HSPB1 and different clinical indicators in patients with breast cancer
From: High HSPB1 expression predicts poor clinical outcomes and correlates with breast cancer metastasis
Characteristic | Low expression of HSPB1 | High expression of HSPB1 | p |
|---|---|---|---|
n | 541 | 542 | Â |
Age, n (%) | Â | Â | 0.133 |
  <  = 60 | 313 (28.9%) | 288 (26.6%) |  |
  > 60 | 228 (21.1%) | 254 (23.5%) |  |
T stage, n (%) | Â | Â | 0.409 |
 T1 | 143 (13.2%) | 134 (12.4%) |  |
 T2 | 321 (29.7%) | 308 (28.5%) |  |
 T3 | 62 (5.7%) | 77 (7.1%) |  |
 T4 | 15 (1.4%) | 20 (1.9%) |  |
N stage, n (%) | Â | Â | 0.003 |
 N0 | 282 (26.5%) | 232 (21.8%) |  |
 N1 | 175 (16.4%) | 183 (17.2%) |  |
 N2 | 52 (4.9%) | 64 (6%) |  |
 N3 | 26 (2.4%) | 50 (4.7%) |  |
M stage, n (%) | Â | Â | 0.403 |
 M0 | 469 (50.9%) | 433 (47%) |  |
 M1 | 8 (0.9%) | 12 (1.3%) |  |
Pathologic stage, n (%) | Â | Â | 0.032 |
 Stage I | 91 (8.6%) | 90 (8.5%) |  |
 Stage II | 327 (30.8%) | 292 (27.5%) |  |
 Stage III | 102 (9.6%) | 140 (13.2%) |  |
 Stage IV | 7 (0.7%) | 11 (1%) |  |
ER status, n (%) |  |  |  < 0.001 |
 Negative | 187 (18.1%) | 53 (5.1%) |  |
 Positive | 330 (31.9%) | 463 (44.7%) |  |
PR status, n (%) |  |  |  < 0.001 |
 Negative | 225 (21.8%) | 117 (11.3%) |  |
 Positive | 290 (28%) | 398 (38.5%) |  |
HER2 status, n (%) | Â | Â | 0.337 |
 Negative | 295 (40.6%) | 263 (36.2%) |  |
 Positive | 78 (10.7%) | 79 (10.9%) |  |